Abstract
Glucocorticoids are commonly used for the treatment of various medical conditions such as autoimmune diseases, inflammatory conditions, and organ transplantation [1–3]. Long-term or high-dose usage of glucocorticoids has been associated with an increased risk of osteonecrosis, particularly in the femoral head [4–8]. Since 1957, when the first case of osteonecrosis of the femoral head (ONFH) after the use of glucocorticoid was reported, many human and animal studies identified the glucocorticoid use as a leading cause of ONFH [4–12].
| Original language | English |
|---|---|
| Title of host publication | Osteonecrosis, Second Edition |
| Publisher | Springer Singapore |
| Pages | 123-128 |
| Number of pages | 6 |
| ISBN (Electronic) | 9789819752393 |
| ISBN (Print) | 9789819752386 |
| DOIs | |
| State | Published - 1 Jan 2024 |
Bibliographical note
Publisher Copyright:© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2024.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ARCO
- Criteria
- Delphi
- Femoral head
- Glucocorticoid
- Osteonecrosis
Fingerprint
Dive into the research topics of 'ARCO Classification Criteria of Glucocorticoid-Associated Osteonecrosis of the Femoral Head'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver